期刊
ONCOLOGY REPORTS
卷 33, 期 3, 页码 1201-1206出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/or.2015.3707
关键词
RhoGDI2; E-cadherin; pancreatic carcinoma; prognosis
类别
资金
- Nature Science Foundation of China [81201905]
- Nature Science Research Grants at the University of Jiangsu Province of P.R. China [14KJB320019]
- Project of Medical Research of Jiangsu Province [Q201402]
Rho GDP dissociation inhibitor 2 (RhoGDI2) has been found to be a regulator of tumor metastasis. However, the expression of RhoGDI2 and its clinicopathological significance as well as the pathway of RhoGDI2 in tumor metastasis have yet to be investigated. To investigate the role of RhoGDI2 in the progression and prognosis of pancreatic carcinoma (PC), the expression of RhoGDI2 in human PC tissues was examined and compared with the clinicopathological characteristics and prognosis. Moreover, the relationship between RhoGDI2 and E-cadherin was examined. The results indicated that RhoGDI2 was overexpressed in PC tissues and associated with clinicopathological characteristics, including clinical stage and lymph node metastasis. Patients with a RhoGDI2-negative expression had a significantly longer survival time than those with a RhoGDI2-positive expression. Additionally, the expression of RhoGDI2 was negatively correlated with the expression of E-cadherin in PC tissues. Taken together, the findings suggest that RhoGDI2 is important in the progression and prognosis of PC, and may be used as a potential prognostic biomarker and a therapeutic target for PC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据